Poor
Not Aligned
Patient Risk:
High
Summary
While many approved-indication and mechanism statements match the provided label excerpts, most efficacy, dosing schedule, adverse-event incidence, and “rare”/monitoring risk characterizations are not supported by the supplied prescribing information excerpts.
Category Scores
Accurate Statements
Dupixent is indicated for adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
1.1 / 14.1
Dupixent is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma.
1.2 / 14.1
Dupixent binds to the IL-4Rα subunit and inhibits IL-4 and IL-13 signaling.
11 DESCRIPTION / 12.1
Dupixent is indicated as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
1.3
Dupixent is indicated for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE).
1.4
Dupixent is indicated for the treatment of adult patients with prurigo nodularis (PN).
1.5
Dupixent is indicated as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.
1.6
Conjunctivitis and keratitis adverse reactions are reported in clinical trials.
5.2
Hypersensitivity reactions (including anaphylaxis and others) have been reported; if clinically significant hypersensitivity occurs, institute appropriate therapy and discontinue DUPIXENT.
5.1
Unsupported Statements
Dupixent is administered by injection every two to four weeks after loading doses.
The provided label excerpts do not include a specific administration interval (2–4 weeks) or a loading-to-maintenance schedule.
In clinical trials for eczema, over 70% of patients achieved clear or almost clear skin with Dupixent.
No numeric eczema efficacy results are present in the supplied excerpts.
For eczema, Dupixent reduces itch and rash severity.
No itch/rash severity efficacy statements are present in the supplied excerpts.
For asthma, Dupixent targets the IL-4/IL-13 pathway to reduce exacerbations.
The mechanism/IL-4/IL-13 pathway is supported, but the explicit claim to 'reduce exacerbations' is not shown in the supplied excerpts.
In asthma trials, Dupixent reduced exacerbations by up to 67%.
No numeric exacerbation reduction results are present in the supplied excerpts.
In asthma trials, Dupixent improved lung function.
No lung function efficacy statements are present in the supplied excerpts.
In asthma trials, Dupixent showed especially greater effects in patients with high eosinophil counts or allergies.
No subgroup-specific superiority claims for high eosinophils/allergies are present in the supplied excerpts.
Injection-site reactions occur in 10-20% of users of Dupixent.
No incidence percentage for injection-site reactions is provided in the supplied excerpts.
Conjunctivitis occurs in 10-20% of users of Dupixent.
The supplied excerpts describe conjunctivitis frequencies in specific populations (e.g., AD, CRSwNP, PN), but do not provide a universal 10–20% incidence statement.
Joint pain occurs in 10-20% of users of Dupixent.
No incidence percentage for joint pain is provided in the supplied excerpts.
Serious infections are rare in users of Dupixent but are monitored.
The supplied excerpts do not provide an incidence characterization such as 'rare' for serious infections, nor monitoring language.
Hypersensitivity is rare in users of Dupixent but is monitored.
The supplied excerpts report hypersensitivity reactions and discontinuation guidance if clinically significant, but do not state hypersensitivity is 'rare' or framed as 'monitored' in the way claimed.
Contradictions
Low
AI Statement
Dupixent is used for chronic obstructive pulmonary disease with type 2 inflammation.
Label Reference
1.6 (states eosinophilic phenotype in inadequately controlled COPD; 'type 2 inflammation' wording not provided in the supplied excerpt).
Important Omissions
Boxed warnings and other labeling content not provided in the supplied excerpts (including any pregnancy, contraindications, and full warnings/precautions details).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Several statements potentially affect dosing safety and risk perception but are not supported by the supplied label excerpts (e.g., maintenance interval claim; multiple adverse-event incidence percentages; and 'rare'/'monitored' framing for serious infections and hypersensitivity).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Large portion of the response contains efficacy, dosing, adverse-event incidence, and risk-characterization claims that are not supported by the provided prescribing information excerpts.
Suggested Improvement
Restrict claims to those explicitly supported by the supplied label excerpts (approved indications, and IL-4/IL-13 mechanism language). Remove or re-quote dosing intervals, numeric efficacy outcomes, universal adverse-event percentages, and any 'rare/monitored' risk characterizations unless the provided label text includes them.